UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

  

 

 

Date of Report (Date of earliest event reported): July 29, 2013

 

InspireMD, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-35731   26-2123838
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)
     

 

4 Menorat Hamaor St.

Tel Aviv, Israel

   67448
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: 972-3-691-7691

  

 
(Former name or former address, if changed since last report)

 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 8.01 Other Events.

 

On July 29, 2013, InspireMD, Inc. (the “Company”) issued a press release announcing that the Company enrolled its first patient in the Master II IDE clinical trial to evaluate the safety and effectiveness of the Company’s MGuard™ Prime Embolic Protection Stent in patients suffering from ST Elevation Myocardial Infarction. The results of the trial are intended to support the Company’s Investigational Device Exemption application with the U.S. Food and Drug Administration to market the MGuard Prime MicroNet™ covered coronary stent system in the U.S.

 

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit Number   Description
99.1  

Press release dated July 29, 2013 

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  inspiremd, inc.
       
       
Date: July 30, 2013 By: /s/ Craig Shore
    Name: Craig Shore
    Title: Chief Financial Officer

  

 
 

 

EXHIBIT INDEX

 

 

Exhibit Number   Description
99.1  

Press release dated July 29, 2013